Guangdong Hengqin Xinchuangyi Biopharmaceutical

Xinchuangyi Biopharmaceutical is a clinical-stage biotechnology company based in the Hengqin New Area of Guangdong, China, specializing in the discovery and development of innovative small molecule drugs targeting nuclear receptors. The company leverages a proprietary technology platform to design highly selective modulators for the treatment of endocrine-related cancers and inflammatory disorders. Its lead candidate, XCY-2, is a next-generation selective estrogen receptor degrader (SERD) currently undergoing clinical evaluation for advanced breast cancer. Xinchuangyi aims to address unmet medical needs in oncology and immunology through the development of oral, high-potency therapies with improved safety profiles compared to existing standards of care.